Drug Type Monoclonal antibody |
Synonyms LILRB1 program (Jounce Therapeutics) |
Target |
Action inhibitors |
Mechanism LILRB1 inhibitors(Leukocyte immunoglobulin-like receptor B1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lymphoma | Discovery | United States | 26 Mar 2023 |